AAccure Therapeutics
Accure Therapeutics is a Barcelona-based, clinical-stage pharma R&D company developing disease-modifying medicines for central nervous system diseases, with a portfolio of three drug candidates (ACT-01, ACT-02, ACT-03) targeting optic neuritis, multiple sclerosis, Parkinson's disease and epilepsy.
SectorsBiotech, Pharma R&D, CNS therapeutics, Neurology
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Founders
L
Laurent Nguyen
Founding CEO & Board Member
P
Pablo Villoslada
Co-founder, Chief Scientific Officer & Chairman of Scientific Advisory Boards
Global models 5
CCerevel Therapeutics
United States · www.cerevel.com ↗
Clinical-stage CNS-focused biotech built by integrating in-licensed neuroscience assets, later acquired by AbbVie, closely mirroring Accure's disease-modifying CNS drug-development model.
$400MComparable
AAlector
United States · www.alector.com ↗
VC-backed clinical-stage biotech developing disease-modifying immuno-neurology therapies for neurodegenerative diseases, same therapeutic-area thesis as Accure.
$355MComparable
DDenali Therapeutics
United States · www.denalitherapeutics.com ↗
Heavily VC-funded clinical-stage biotech focused on disease-modifying treatments for neurodegenerative CNS disorders, comparable science-driven CNS platform model.
$340MComparable
A
Annexon Biosciences
United States · www.annexonbio.com ↗
Clinical-stage biotech targeting complement-mediated neuroinflammatory and neurodegenerative diseases, closely matching Accure's neuroinflammation focus (optic neuritis, MS).
$140MComparable
VVigil Neuroscience
United States · www.vigilneuro.com ↗
VC-backed (Atlas Venture, GV) clinical-stage biotech developing disease-modifying therapies for neurodegenerative diseases, similar early-stage CNS asset-development model to Accure.
$115MComparable
In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 2
Open as list →
Funding rounds 1
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2020-05-26 | Series A | €7.6M |
Alta Life Sciences
+1 more
|
News 5
Open as list →| Published | Article |
|---|---|
| 2026-03-30 |
Six promising biotech companies to know in Barcelona ↗
Labiotech.eu
2026-03-30 |
| 2026-01-06 |
FDA grants breakthrough therapy designation to Oculis' privosegtor for optic neuritis ↗
Ophthalmology Times
2026-01-06 |
| 2025-04-07 |
Accure Therapeutics awarded a total of $1.6M in grants from The Michael J. Fox Foundation and Fonds National de Recherche de Luxembourg to bring first-in-class drug for Parkinson's disease to clinical trials ↗
Accure Therapeutics (press release)
2025-04-07 |
| 2025-04-07 |
Accure Therapeutics secures $1.6M from Michael J. Fox Foundation and Luxembourg's national research Fund ↗
Tech.eu
2025-04-07 |
| 2025-01-10 |
Accure Therapeutics partner Oculis reached positive phase 2 results for lead neuroprotective therapy ↗
PharmiWeb
2025-01-10 |